The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease

Virginia Wang, Helene Vilme, Matthew L. Maciejewski, Leigh Boulware

Research output: Contribution to journalReview article


The growing prevalence and progression of chronic kidney disease (CKD) raises concerns about our capacity to manage its economic burden to patients, caregivers, and society. The societal direct and indirect costs of CKD and end-stage renal disease are substantial and increase throughout disease progression. There is significant variability in the evidence about direct and indirect costs attributable to CKD and end-stage renal disease, with the most complete evidence concentrated on direct health care costs of patients with advanced to end-stage CKD. There are substantial gaps in evidence that need to be filled to inform clinical practice and policy.

Original languageEnglish (US)
Pages (from-to)319-330
Number of pages12
JournalSeminars in Nephrology
Issue number4
Publication statusPublished - Jul 1 2016
Externally publishedYes



  • Chronic kidney disease
  • costs
  • economics
  • end-stage renal disease

ASJC Scopus subject areas

  • Nephrology

Cite this